Holen Sie sich die Stockscreener-App
1.17
0.86%
0.01
Handel nachbörslich:
1.20
0.03
+2.56%
Schlusskurs vom Vortag:
$1.16
Offen:
$1.15
24-Stunden-Volumen:
1.71M
Relative Volume:
0.52
Marktkapitalisierung:
$152.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.17M
KGV:
-1.5673
EPS:
-0.7465
Netto-Cashflow:
$-85.97M
1W Leistung:
+13.59%
1M Leistung:
-4.88%
6M Leistung:
+24.47%
1J Leistung:
+17.59%
1-Tages-Spanne:
$1.14
$1.23
1-Wochen-Bereich:
$1.06
$1.23
52-Wochen-Spanne:
$0.5062
$1.51
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.17 | 151.34M | 0 | -97.17M | -85.97M | -0.7465 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2025-11-07 | Eingeleitet | Roth Capital | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
If You Invested $1,000 in Immunic Inc (IMUX) - Stock Titan
IMUX SEC FilingsImmunic Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Immunic to offer up to 458.2 million shares of common stock registered for resale by selling stockholdersSEC filing - marketscreener.com
Immunic To Offer Up To 458.2 Million Shares Of Common Stock Registered For Resale By Selling StockholdersSEC Filing - TradingView
According to the latest filing with the U.S. Securities and Exchange Commission (SEC), the biopharmaceutical company Immunic, Inc. has initiated an equity resale program. - Bitget
Immunic (NASDAQ: IMUX) registers 458.2M resale shares after $200M private placement - Stock Titan
Immunic Regains Nasdaq Compliance, Stabilizing Listing Status - The Globe and Mail
Immunic regains Nasdaq minimum bid price compliance By Investing.com - Investing.com South Africa
Immunic, Inc. (IMUX) stock price, news, quote and history - Yahoo Finance UK
IMUX Forecast, Price Target & Analyst Ratings | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement - Sahm
Immunic, Inc. (IMUX) latest stock news and headlines - sg.finance.yahoo.com
Immunic Regains Nasdaq Compliance as IMUX Stock Maintains Minimum Bid Price Requirement - Minichart
Immunic regains Nasdaq minimum bid price compliance - Investing.com
Immunic Regains Nasdaq Minimum Bid Price Compliance After 20 Consecutive Business Days - TradingView
[8-K] IMMUNIC, INC. Reports Material Event - Stock Titan
Immunic AG / US4525EP1011 - AD HOC NEWS
Immunic appoints Jon Congleton to board of directors By Investing.com - Investing.com Australia
Immunic (IMUX) director Jon Congleton files initial Form 3 - Stock Titan
Immunic Appoints Biopharma Leader Jon Congleton to Board, Advancing MS Therapy Toward Phase 3 Pivotal Readouts - Minichart
Small cap wrap: BioHarvest Sciences, American Resources, First Phosphate, Immunic... - Proactive financial news
Immunic Adds Veteran Biopharma Leader to Board - tipranks.com
Immunic appoints biopharmaceutical executive Jon Congleton to board - Yahoo! Finance Canada
Immunic Appoints Jon Congleton To Board - citybiz
Immunic appoints Jon Congleton to board of directors - Investing.com
Biopharmaceutical company Immunic, Inc. recently announced the appointment of experienced industry executive Jon Congleton to its board of directors. - Bitget
Veteran biotech leader Jon Congleton joins Immunic (NASDAQ: IMUX) board - Stock Titan
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - ChartMill
Smart Money: Is Immunic Inc stock a good dividend stock2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
Growth Review: Is Immunic Inc undervalued by DCF analysisMarket Movement Recap & Fast Gaining Stock Reports - baoquankhu1.vn
Pharma News: Whats next for Immunic Inc stock2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
Immunic Inc Stock Warning Signs - gurufocus.com
Guggenheim initiates coverage of Immunic (IMUX) with buy recommendation - MSN
Immunic stock jumps after Guggenheim initiates with Buy By Investing.com - ca.investing.com
Immunic (IMUX) Gains on Guggenheim's Buy Rating and Promising Dr - GuruFocus
Immunic stock jumps after Guggenheim initiates with Buy - Investing.com UK
Immunic stock gains new Buy at Guggenheim (IMUX:NASDAQ) - Seeking Alpha
Immunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
IMUX: Guggenheim Initiates Coverage with a Buy Rating and $7 Pri - gurufocus.com
Guggenheim Initiates Coverage on Immunic With Buy Rating, $7 Price Target - marketscreener.com
Immunic stock initiated at Buy by Guggenheim on MS therapy potential By Investing.com - za.investing.com
Immunic stock initiated at Buy by Guggenheim on MS therapy potential - Investing.com South Africa
Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Tangible book value per share of Immunic, Inc. – FWB:10VA - TradingView
Bull Bear: Does Immunic Inc meet Warren Buffetts criteria2026 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
US Stocks Recap: Will Immunic Inc stock recover after earningsFed Meeting & Weekly Return Optimization Alerts - baoquankhu1.vn
Immunic, Inc. (IMUX) announces European patent grant for vidofludimus calcium - MSN
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium - Insider Monkey
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next - MarketBeat
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug By Investing.com - Investing.com Canada
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug - Investing.com
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunic Inc-Aktie (IMUX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):